Novel 3D printing concept for the fabrication of time-controlled drug delivery systems varying complexities and shows that customization of drug products is possible. This will enable future improvements in patient-specific drug therapies and the mastering of several challenges related to the manufacturing and marketing of personalized drug delivery systems [1] [2] [3] . The application of 3D printing for the manufacturing of DDS has been investigated since the early 1990s. An important milestone in this context was the approval of the first 3D printed pharmaceutical product by the US FDA in 2016 [1] .
Stereolithography (SLA) is one of the preferred technologies for printing DDS because it offers high precision and the possibility to adjust the drug-release kinetics by a defined crosslinking of the photocurable resin [4] . In SLA a thin defined layer of a photocurable resin is selectively exposed to light. The light initiates a radical polymerization reaction and leads to a local curing of the irradiated resin. As soon as the curing process is finished the platform is lowered according to a defined layer thickness. A recoater flattens the resin surface and selective curing of the new layer starts. These steps are repeated until the building process has finished. In general, a laser is used as irradiation source. The beam is guided by scan optics. Another possibility is to mount the laser head (e.g. diode laser) directly onto a linear actuator and to irradiate the resin surface line by line [5] .
The use of LEDs as light source is also possible and they have several advantages over lasers: LEDs are relatively cheap, have a low energy consumption, have a high monochromaticity and can be replaced very fast to re-fit for a new application. LED technology has made great progress in recent times. There is a great variety of LEDs with different wavelengths and radiant fluxes available on the market [6] . Especially for the development of new resin formulations for biomedical applications, the advantages of LED technology can prove useful because the wavelength of the LED light source can easily be adapted to the absorption spectrum of the photoinitiator, which leads to a reduced concentration of photoinitiator in the resin and therefore to a better biocompatibility.
Another process successfully used in pharmaceutical and biomedical applications is inkjet printing. Inkjet printing allows a precise dosage and positioning of droplets containing volumes of picolitres. Therefore, inkjet printing Abstract: Three-dimensional (3D) printing has become a popular technique in many areas. One emerging field is the use of 3D printing for the development of 3D drug delivery systems (DDS) and drug-loaded medical devices. This article describes a novel concept for the fabrication of timecontrolled drug delivery systems based on stereolithography combined with inkjet printing. An inkjet printhead and an UV-LED light source have been integrated into an existing stereolithography system. Inkjet printing is used to selectively incorporate active pharmaceutical ingredients (API) during a stereolithographic 3D printing process. In an initial experimental study, poly (ethylene glycol) diacrylate (PEGDA) was used as polymer whereas 2-Hydroxy-4´-(2-hydroxyethoxy)-2-methylpropiophenone (Irgacure 2959) and Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) were used as photoinitiators. Basic structures could be manufactured successfully by the new hybrid 3D printing system. 
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Introduction
3D printing has a high potential for the manufacturing of 3D drug delivery systems (DDS) and drug-loaded medical devices. 3D printing enables the fabrication of DDS with can be used, for instance, to deposit drugs into micro-sized reservoirs on implant surfaces [7, 8] .
This study reports on a novel 3D-printing concept that combines SLA and inkjet printing leading to a novel hybrid 3D printing system. Inkjet printing is used to selectively incorporate active pharmaceutical ingredients (API) during a stereolithographic 3D printing process. This opens up broad prospects for the creating of novel types of DDS featuring the following advantages:
 release of different drugs in one DDS,  retarding release or defined start and period of drug release,  gradient of incorporated drug over time.
The concept for combining SLA and inkjet-printing as well as first experimental results using a poly (ethylene glycol) diacrylate (PEGDA) based resin are presented.
Materials and methods
Concept
The idea is to manufacture a new type of drug delivery system (DDS) with selectively incorporated active pharmaceutical ingredients (API). The base structure of the DDS will be created by SLA using a photosensitive resin. Previous studies already focused on 3D printed DDS using a PEGDA based resin containing APIs [9, 10] . The novelty of the concept presented here is that the base structure is built from a resin without APIs. The APIs are then incorporated into selected areas of the base structure by an inkjet module. This allows the manufacturer to adjust the release kinetics of the drugs by choosing an appropriate local position of the drug depot (e.g. drug depots in the middle of a structure or a drug depot with a gradient from inside to outside). Additionally, it will be possible to connect the APIs to special crosslinker-molecules, to influence the release kinetics in a chemical way. Figure 1 shows a schematic illustration of the novel 3D printing apparatus and a scheme of the building process of one layer.
The process is similar to the classic SLA process already described in the literature [11] . Additional to the light source, inkjet-modules are attached to a movable x-y-axis. On the right side of Figure 1 the creation of one layer is illustrated. The light cures the base structure (outline indicated by the grey dashed line) of liquid photosensitive resin line by line. If the layer is intended to contain APIs, the inkjet printhead drops the desired amount of API solution to the specified areas. Afterwards, the drops are cured with the resin so that the APIs are fixed in the polymer matrix. These steps are repeated layer by layer until the building process is completed. The aim is to build structures with drug depots located e.g. in the center of the structure. Figure 2 shows a schematic illustration of a base structure with two drug depots (red and green). Since 3D printing is used for the manufacturing, the complexity of the DDS can be varied according to the specific applications. 
Modification of the (micro)-stereolithography apparatus
A (micro-)-stereolithography apparatus based on a diode laser and linear axis has been previously developed at our institute. Details of the apparatus have been published [5] . This apparatus was now used to establish the new combined SLA and inkjet process. In order to enhance the flexibility with regard to the light exposure the diode laser has been replaced by a UV-LED technology. In order to focus the LED light, an adapted optics had to be developed. UV-LEDs with different wavelengths (Seoul Viosys, Ansan, South Korea) were chosen as light source (see Table 1 ). In order to minimize the concentration of the photoinitiator in the resin, the wavelength of the LED light source should match the absorption spectrum of the photoinitiator. Therefore, various UV-LEDs have been chosen for initial tests.
To achieve nearly the same resolution as the diode laser system, different types of lenses and a mirror have been assembled to focus the light.
The piezoelectric microdispenser type Nano-Tip HV-J (GESIM, Großerkmannsdorf, Germany) has been integrated in the SLA apparatus. The printheads are used for printing the drug depots.
Initial experiments
Initial experiments were performed using PEGDA as the base polymer. To maintain biocompatibility 2-Hydroxy-4´-(2-hydroxyethoxy)-2-methylpropiophenone (Irgacure 2959) or Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) were used as photoinitiator, since these photoinitiators are well known for their good biocompatibility. Lines and simple geometries like cubes have been printed in order to adjust the printing parameter like velocity v, radiant flux P and wavelength λ.
The characterization of the initially printed structures were carried out with the aid of a confocal laser scanning microscope (CLSM) LEXT OLS 4000, Olympus (Tokyo, Japan).
Results
The UV-LED technology and the inkjet printhead have been successfully installed in the SLA apparatus and integrated into the existing computer-based control system. Technical details of the hybrid 3D printing system are depicted in Figure 3 . After successfully curing single lines, areas have been solidified line by line. After this, the first 3D cubic structure was printed. The height of the structure is about 1 mm. Details of the structure are depicted in Figure 5 . The curing lines can be recognized at the top of the structure. The lines have a distance of 50 µm. the height is about 1 mm, the distance of the lines is 50 µm.
Conclusion
The hybrid technology of SLA and inkjet-printing has high potential for future manufacturing of 3D drug delivery systems and drug-loaded medical devices. The implementation of the technical concept could be successfully demonstrated. Initial experimental studies show that simple structures can be manufactured based on PEGDA based resin. The new UV-LED technology allowed the experimenters to reduce the photoinitiator concentration of the PEGDA based resin. The next steps will be the commissioning of the inkjet modules and an extensive validation of the hybrid 3D printing process.
